A new study describes a high-throughput strategy for engineering bispecific antibodies that could help macrophages destroy malignant B cells more efficiently, offering a potential new route for improving immunotherapy against B-cell lymphoma. Published in Nature Communications in 2026 by Pagès-Geli, Ribeiro, Wienclaw and colleagues, the work focuses on an immune cell that has often received less attention than T cells in cancer treatment: the macrophage.
Macrophages are professional scavengers of the immune system. They patrol tissues, recognize abnormal cells and remove cellular debris, microbes and damaged material. In cancer, however, malignant cells can suppress or evade macrophage activity, allowing tumors to persist despite the presence of immune cells. The new research addresses this problem by using bispecific antibodies, engineered proteins designed to bind two different targets at the same time.
One arm of a bispecific antibody can recognize an antigen displayed on the surface of a lymphoma cell, while the other can engage an activating receptor on a macrophage. By physically linking the immune cell to its target, the molecule may increase the probability that the macrophage will form a stable contact with the cancer cell and initiate engulfment. This process, known as antibody-dependent cellular phagocytosis, can result in the internalization and destruction of the malignant cell.
The central challenge is that antibody design involves numerous variables. Researchers can alter the regions that bind tumor-associated antigens, the affinity with which those regions interact with their targets and the structural properties of the antibody’s Fc domain, which communicates with immune-cell receptors. Small changes in geometry, spacing, binding strength or receptor engagement can substantially affect how an antibody behaves in a complex biological environment.
To explore this design space, the team developed a high-throughput engineering approach. Rather than testing a limited number of antibody candidates one by one, high-throughput methods allow researchers to create and evaluate large collections of variants in parallel. Such screening can reveal combinations of molecular features that promote stronger macrophage responses while reducing undesirable activity, weak target binding or inefficient assembly.
This approach is particularly relevant to B-cell lymphoma, a group of cancers that arise from abnormal B lymphocytes. Many lymphoma cells carry surface proteins that distinguish them from most healthy tissues, creating opportunities for targeted therapies. Yet the presence of a recognizable tumor antigen alone does not guarantee that an immune cell will eliminate the cancer. A successful therapeutic antibody must also recruit the right effector mechanism and deliver a sufficiently strong signal to overcome the tumor’s defensive environment.
Bispecific antibodies may provide that additional control because they can be designed to coordinate two biological events simultaneously. One binding site identifies the cancer cell, establishing specificity, while the second can influence the behavior of the macrophage. The resulting immune synapse is different from the interaction created by a conventional antibody, and its effectiveness may depend on the precise molecular architecture of the engineered protein. High-throughput screening is therefore useful for identifying candidates that perform well as complete molecular systems rather than merely showing strong binding in isolation.
The study’s macrophage-centered perspective also reflects a broader shift in cancer immunology. T-cell therapies have transformed treatment for several blood cancers, but macrophages are abundant in many tumors and can possess powerful engulfment machinery. Their activity is governed by a balance between activating and inhibitory signals. Therapeutic antibodies that improve target recognition or strengthen activating receptor engagement could potentially tip that balance toward tumor clearance. At the same time, careful engineering is essential, since excessive immune activation could damage healthy cells or provoke inflammatory side effects.
The researchers’ findings support the idea that antibody therapeutics can be optimized through systematic molecular design rather than trial and error alone. By connecting large-scale variant generation with functional testing, the platform may accelerate the discovery of bispecific molecules capable of producing robust macrophage-mediated cytotoxicity. The approach could also be adapted to other cancers in which tumor cells display suitable surface markers and macrophages are present in the tumor microenvironment.
The work does not eliminate the hurdles between an engineered antibody and a clinical treatment. Promising candidates must still be evaluated for stability, manufacturability, pharmacokinetics, tissue distribution, off-target binding and safety. Tumors can also vary widely in antigen expression and immune composition, meaning that an antibody effective in one lymphoma subtype may perform differently in another. Even so, the study presents a compelling framework for turning macrophages into more precise cancer-fighting agents. By combining the targeting power of bispecific antibodies with the destructive capacity of innate immune cells, high-throughput protein engineering could help open a new chapter in lymphoma immunotherapy.
Subject of Research: High-throughput engineering of bispecific antibodies to enhance macrophage-mediated cytotoxicity against B-cell lymphoma.
Article Title: High-throughput engineering of bispecific antibodies to enhance macrophage-mediated cytotoxicity of B-cell lymphoma.
Article References: Pagès-Geli, C., Ribeiro, J., Wienclaw, T. et al. “High-throughput engineering of bispecific antibodies to enhance macrophage-mediated cytotoxicity of B-cell lymphoma.” Nature Communications (2026). https://doi.org/10.1038/s41467-026-76180-5
Image Credits: AI Generated
DOI: 10.1038/s41467-026-76180-5
Keywords: bispecific antibodies, macrophages, B-cell lymphoma, cancer immunotherapy, antibody engineering, cellular cytotoxicity, high-throughput screening, immuno-oncology
